drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Monoclonal antibody immunotherapy that binds and blocks LAIR-1 (CD305), antagonizing collagen/C1q-triggered ITIM signaling via SHP-1/2 to relieve immune suppression and potentially directly target LAIR-1–expressing leukemic blasts and stem/progenitor cells.
nci_thesaurus_concept_id
C199599
nci_thesaurus_preferred_term
Anti-LAIR1 Monoclonal Antibody NC525
nci_thesaurus_definition
A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; LAIR-1; CD305), with potential antineoplastic activity. Upon administration, anti-LAIR1 monoclonal antibody NC525 targets, binds to and inhibits LAIR1-mediated downstream survival signaling. In addition, NC525 induces Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This inhibits survival of LAIR1-expressing acute myeloid leukemia (AML) leukemic stem cells (LSCs) and blast cells, and decreases tumor cell proliferation. LAIR1, an immune inhibitory checkpoint receptor, is overexpressed in AML LSCs and blast cells while having a minimal expression on normal, healthy hematopoietic stem cells (HSCs.). LAIR1 plays a key role in mediating survival signaling in these tumor cells.
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1k monoclonal antibody that binds and blocks LAIR‑1 (CD305), antagonizing collagen/C1q-triggered ITIM signaling via SHP‑1/2 to relieve immune suppression; additionally leverages Fc effector functions (ADCC/ADCP) to deplete LAIR‑1–expressing AML leukemic stem and blast cells, reducing survival and proliferation.
drug_name
NC525
nct_id_drug_ref
NCT05787496